Complete genome sequence of pathogenic Pseudomonas aeruginosa strain P4 associated with persistent lung infections
Ravali Arugonda, Namrata Bonde, Nicholas Dillon

TL;DR
This paper presents the full genome sequence of a drug-resistant Pseudomonas aeruginosa strain linked to long-term lung infections.
Contribution
The contribution is the circularized whole genome sequence of a clinically relevant, multi-drug resistant Pseudomonas aeruginosa strain.
Findings
The genome sequence of Pseudomonas aeruginosa strain P4 has been fully circularized.
Strain P4 is a multi-drug resistant clinical isolate associated with persistent lung infections.
The sequence provides a resource for studying antibiotic resistance in P. aeruginosa.
Abstract
Here we are reporting the circularized whole genome sequence of multi-drug resistant Pseudomonas aeruginosa strain P4, a clinical human lung isolate. This strain has previously been used to study antibiotic resistance in P. aeruginosa.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
| Genomic features (P4) | Chromosome | Plasmid |
|---|---|---|
| Strain ID | P4 | |
| SRA accession no. |
| |
| GenBank accession no. |
|
|
| Total no. of raw nanopore reads | 239,640 | |
| N50 of nanopore reads (bp) | 11,394 | |
| Total no. of Illumina reads (R1 +R2) | 7,369,882 | |
| No. of contigs | 1 | |
| Total length (bp) | 6,670,990 | 47,865 |
| Coverage of total genome (×) | 319 | |
| GC content (%) | 66.25 | 59.12 |
| No. of predicted genes | 6,339 | |
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAntibiotic Resistance in Bacteria · Genomics and Phylogenetic Studies · Bacterial biofilms and quorum sensing
ANNOUNCEMENT
Multi-drug resistant (MDR) Pseudomonas aeruginosa is one of the ESKAPE pathogens and a leading cause of morbidity and mortality (1). In this announcement, we report the assembled complete genome sequence of P. aeruginosa strain P4, a clinical sputum sample originally obtained from a tertiary academic hospital in the New York metropolitan area (2). The strain was kindly provided to us by Dr. Victor Nizet (UCSD). Previous studies have been done on P4 in evaluating synergistic antibiotic combinations and antimicrobial peptides (2–4), understanding the effect of host environmental factors on immune responses (5), and in non-antibiotic disinfection strategies (6, 7). Here, we present a complete, circularized genome assembly of P4, comprising a chromosome and one plasmid. This published genome will be useful for studying the metabolism, mechanisms of antibiotic resistance, and virulence of the clinical P. aeruginosa strain P4. Genome assembly and annotation metrics are summarized in Table 1.
DNA from P4 was extracted following the Qiagen DNeasy Blood and Tissue kit (Cat#69504) instructions. Adapted from (8), P4 DNA was isolated via first resuspension of pellets from overnight cultures grown in cation-adjusted Mueller Hinton Broth (CA-MHB) at 37°C, 200 rpm in 1× TAE buffer (Tris, Acetic acid, EDTA) followed by centrifugation and resuspension in enzymatic lysis buffer (20 mM Tris-Cl, 2 mM EDTA, 1.2% Triton-X-100) and 50 mg/mL lysozyme. RNase A was then added, and the mixture was incubated at 37°C for 2 h. 25 µL of Proteinase K and 200 µL of AL buffer were added and incubated for 30 min at 56°C on a heat block (VWR). Qiagen kit instructions were followed exactly for the ethanol addition and DNA elution.
Hybrid sequencing was performed by SeqCenter (Pittsburgh, PA). Illumina sequencing libraries were prepared using the tagmentation-based and PCR-based Illumina DNA Prep kit and custom IDT 10 bp unique dual indices with a target insert size of 280 bp. Illumina sequencing was performed on an Illumina NovaSeq 6000 sequencer, producing 2×151 bp paired-end reads. Demultiplexing, quality control, and adapter trimming were performed with bcl-convert (v4.2.4).
Sample libraries were prepared using the PCR-free Oxford Nanopore Technologies (ONT) Ligation Sequencing Kit (SQK-NBD114.24) with the NEBNext Companion Module (E7180L), following the manufacturer’s instructions. No additional DNA fragmentation or size selection was performed. Sequencing was carried out on an ONT GridION platform using R10.4.1 flow cells in multiplexed runs, with the 400 bp sequencing mode and a minimum read length threshold of 200 bp. Adaptive sampling was not enabled. Guppy (v6.5.7) was used for super-accurate basecalling, demultiplexing, and adapter trimming.
Raw sequenced reads were quality controlled using FastQC (v0.12.1) (9). Trimmomatic (v0.39) (10) trimmed low-quality sequences from raw Illumina reads. Nanofilt (v2.8.0) (11) and porechop (v0.2.4) (12) were used to trim the residual adapter sequence from ONT reads. Illumina and ONT reads were assembled using Unicycler (v0.4.8) (13). Once the assembly was done, contigs were checked for circularization using circlator (v1.5.5) (14). Genome annotation was done using the NCBI Prokaryotic Genome Annotation Pipeline (v6.6) (15). The default parameters were used for all software.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Rice LB. 2008. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 197:1079–1081. doi:10.1086/53345218419525 · doi ↗ · pubmed ↗
- 2Fair RJ, Mc Coy LS, Hensler ME, Aguilar B, Nizet V, Tor Y. 2014. Singly modified amikacin and tobramycin derivatives show increased r RNA A-site binding and higher potency against resistant bacteria. Chem Med Chem 9:2164–2171. doi:10.1002/cmdc.20140217525055981 PMC 4298452 · doi ↗ · pubmed ↗
- 3Dillon N, Holland M, Tsunemoto H, Hancock B, Cornax I, Pogliano J, Sakoulas G, Nizet V. 2019. Surprising synergy of dual translation inhibition vs. Acinetobacter baumannii and other multidrug-resistant bacterial pathogens. E Bio Medicine 46:193–201. doi:10.1016/j.ebiom.2019.07.04131353294 PMC 6711115 · doi ↗ · pubmed ↗
- 4Holland M, Bjanes E, Nizet V, Dillon N. 2022. Bicarbonate modulates delafloxacin activity against MDR Staphylococcus aureus and Pseudomonas aeruginosa. J Antimicrob Chemother 77:433–442. doi:10.1093/jac/dkab 42134893834 PMC 8809187 · doi ↗ · pubmed ↗
- 5Siew R, Ou T-L, Dahesh S, Akong K, Nizet V. 2022. Bicarbonate effects on antibacterial immunity and mucus glycobiology in the cystic fibrosis lung: a review with selected experimental observations. Infect Microbes Dis 4:103–110. doi:10.1097/im 9.000000000000010136793929 PMC 9928163 · doi ↗ · pubmed ↗
- 6Banerjee B, Thompson C, Nizet V, Bjånes E. 2024. Bactericidal efficacy of low dose gaseous ozone against clinically relevant multidrug-resistant bacteria. Front Microbiol 15:1480433. doi:10.3389/fmicb.2024.148043339723132 PMC 11668732 · doi ↗ · pubmed ↗
- 7Lin L, Kim J, Chen H, Kowalski R, Nizet V. 2016. Component analysis of multipurpose contact lens solutions to enhance activity against Pseudomonas aeruginosa and Staphylococcus aureus. Antimicrob Agents Chemother 60:4259–4263. doi:10.1128/AAC.00644-1627139484 PMC 4914654 · doi ↗ · pubmed ↗
- 8Huo W, Adams HM, Zhang MQ, Palmer KL. 2015. Genome modification in Enterococcus faecalis OG 1RF assessed by bisulfite sequencing and single-molecule real-time sequencing. J Bacteriol 197:1939–1951. doi:10.1128/JB.00130-1525825433 PMC 4420909 · doi ↗ · pubmed ↗
